p21-activated kinases (PAKs) are serine/threonine protein kinases that serve as important mediators of Rac and Cdc42 GTPase function as well as pathways required for Ras-driven tumorigenesis. PAK1 has been implicated in signaling by growth factor receptors and morphogenetic processes that control cell polarity, invasion, and actin cytoskeleton organization. To better understand the role of PAK1 in tumorigenesis, PAK1 genomic copy number and expression were determined for a large panel of breast, lung, and head and neck tumors. PAK1 genomic amplification at 11q13 was prevalent in luminal breast cancer, and PAK1 protein expression was associated with lymph node metastasis. Breast cancer cells with PAK1 genomic amplification rapidly underwent apoptosis after inhibition of this kinase. Strong nuclear and cytoplasmic PAK1 expression was also prevalent in squamous nonsmall cell lung carcinomas (NSCLCs), and selective PAK1 inhibition was associated with delayed cell-cycle progression in vitro and in vivo. NSCLC cells were profiled using a library of pathway-targeted small-molecule inhibitors, and several synergistic combination therapies, including combination with antagonists of inhibitor of apoptosis proteins, were revealed for PAK1. Dual inhibition of PAK1 and X chromosome-linked inhibitor of apoptosis efficiently increased effector caspase activation and apoptosis of NSCLC cells. Together, our results provide evidence for dysregulation of PAK1 in breast and squamous NSCLCs and a role for PAK1 in cellular survival and proliferation in these indications.
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T he p21-activated kinase (PAK) family consists of six members, which are subdivided into two groups: PAK1-3 (group I) and PAK4-6 (group II). This distinction is based on sequence similarities and also, on the presence of an autoinhibitory region in group I PAKs, which is not present in group II PAK proteins (1). As a major downstream effector of the Rho family small GTPases Cdc42 and Rac1, PAK1 plays a fundamental role in controlling cell motility by linking a variety of extracellular signals to changes in actin cytoskeleton organization, cell shape, and adhesion dynamics (2, 3) . PAK1 is widely expressed in a variety of normal tissues, and expression is significantly increased in ovarian, breast, and bladder cancers (4) (5) (6) . Functional studies have also implicated PAK1 in cell transformation (7) , and transgenic overexpression of PAK1 in the mammary gland promotes the formation of malignant tumors and premalignant lesions in animal models, albeit with a long latency (8) . These findings indicate that PAK1 may contribute to tumorigenesis in some disease contexts.
PAK1 has recently been shown to be involved in fundamental cellular processes beyond that of regulating the cytoskeleton, including regulation of apoptosis or programmed cell death (9) . There are published examples that describe activated forms of PAK1 protecting against cell death induced by either cell detachment or chemotherapeutic agents (10, 11) , but the relevant pathways downstream of PAK1 remain only partially understood. For instance, PAK1 has been shown to protect lymphoid progenitor cells from intrinsic apoptotic signals by phosphorylation of B-cell lymphoma 2 (BCL2) antagonist of cell death (BAD) to limit its interaction with BCL2 (12) . In addition, PAK1-mediated phosphorylation of v-raf-1 murine leukemia viral oncogene homolog 1 (C-RAF) at Ser338 can stimulate translocation of C-RAF to the mitochondria and subsequent complex formation with BCL2 in HEK293T cells (13) . However, additional mechanisms may be involved, and the effect of PAK1 inhibition on apoptosis of human tumor cells has yet to be thoroughly investigated. Herein, we use inducible shRNA, and small-molecule approaches were used to explore the dependence of tumor cells on PAK1 signaling to maintain cellular survival, proliferation, and in vivo tumor growth. PAK1 inhibition promoted tumor cell apoptosis as either single-agent treatment (in the context of tumor cells with focal genomic amplification of PAK1) or combination therapy with several targeted agents in squamous cell carcinoma. In particular, antagonists of X chromosome-linked inhibitor of apoptosis (XIAP) protein potently synergized with PAK1 inhibition to induce tumor cell death. Our results show that significant antitumor efficacy is observed after PAK1 inhibition and support further characterization of PAK1 as a therapeutic target.
Results

PAK1 Amplification and Oncogene Addiction in Breast
Cancer. Several genomic regions with copy-number gains have been identified in breast cancer by comparative genomic hybridization approaches (14) . However, the low resolution of older analysis platforms may have resulted in tumor-promoting genes being overlooked (15) . As such, we assayed 51 breast tumors for DNA copy-number changes using high-resolution SNP arrays and analyzed these data using the Genomic Identification of Significant Targets in Cancer (GISTIC) method (15, 16) . A chromosome 11 region of amplification is shown in Fig. 1A . Two distinct GISTIC peaks were observed at 69 and 76 Mb, suggesting that the 11q13.5 region contains two independent amplicons. The 69-Mb peak corresponds to amplification of CCND1, a very well-described genomic alteration in breast cancer (17) , and the plateau of the 76-Mb peak contains the PAK1 gene (shown as a red dotted line in Fig. 1A ). The frequency of PAK1 amplification was 17% (copy number ≥ 2.5) in this tumor panel, and copy-number gain was well-correlated with mRNA expression (Pearson correlation = 0.75) (Fig. 1B) . Similar results were also obtained in a larger panel (n = 165) of breast tumors that were also analyzed for genomic amplification by high-resolution SNP arrays (Table S1 ) (18) . PAK1 gene amplification was prevalent, and mean DNA copy number was greatest in luminal, hormone receptor-positive tumors (7.7 mean copy number) and was least in basal breast tumors (2.8 mean copy number) (Table S1 ). Taken together, this suggests that PAK1 could be a tumor-promoting driver gene in the 76-Mb amplicon of chromosome 11.
To investigate the possible contribution of PAK1 to breast cancer pathophysiology when overexpressed by genomic amplification, we determined the biological response to inhibition of PAK1 in breast cancer cells, with focal 76-Mb amplification on chromosome 11. Gene amplification and elevated expression of PAK1 were observed in luminal-subtype M.D. Anderson Metastatic Breast-175 (MDA-MB-175), human breast cancer cell 1500 (HCC1500), and MDA-MB-134IV breast cancer cell lines (5.7, 4.3, and >8.0 DNA copies, respectively). Inhibition of PAK1 catalytic activity using selective siRNA-mediated knockdown of PAK1 expression resulted in a pronounced induction of apoptosis as determined by Annexin-V/ propidium iodide staining of dying cells (two-to sixfold increase in Annexin-V incorporation) (Fig. 1C) . This phenotype was evident within 48-72 h and was confirmed using inhibitor targeting PAK1 activation-3 (IPA-3), an allosteric inhibitor that binds PAK1-3 and prevents activation by Rho family GTPases (19) (sevenfold increase) (Fig. 1D ). Cell death induced by PAK1 inhibition was also associated with caspase activation, poly-ADP ribose polymerase (PARP) cleavage, and attenuated phosphorylation of MAPK/ERK kinase-1 (MEK1) S298 and ERK1/2 ( Fig. S1 A and B) . Hence, the strong induction of cell death resulting from PAK1 inhibition in breast cancer cells with PAK1 amplification suggests that this kinase can contribute to the oncogenic phenotype, at least in part, by suppressing tumor cell apoptosis. The degree to which cells were sensitive to PAK1 inhibition was also correlated with the level of PAK1 overexpression ( Fig. S1 C and D) . In this way, PAK1 may be an Achilles' heel for this genetically defined subset of breast cancer (20) .
PAK1 Protein Expression in Human Tumors. To follow-up on these observations and determine the possible extent of PAK1 dysregulation across human cancers, PAK1 protein expression level and subcellular localization were ascertained by immunohistochemical (IHC) staining of tissue microarrays. Robust and selective IHC reactivity of PAK1 antibody was confirmed in cancer cell lines with immunoblot analysis of protein extracts from these cells performed in parallel (Fig. S2 A-D) . PAK1 protein expression data for 226 primary breast cancers, 16 breast ductal carcinoma in situ (DCIS), 32 breast cancer lymph node metastases, 97 nonsmall cell lung cancers (NSCLC), 27 small cell lung cancers (SCLC), and 130 head and neck squamous cell carcinomas (HNSCC) are summarized in Table 1 and Fig. S2E . In the context of breast cancer, PAK1 expression was absent in normal breast epithelial cells but was detected in the malignant cells of 39% of primary breast adenocarcinomas (Fig. S2E) . Cytoplasmic expression of PAK1 in early DCIS lesions was similar to expression in primary breast adenocarcinoma (P = 0.64), and PAK1 amplification could, thereby, be an early genetic event in the initiation and progression of some breast tumors. Consistent with the established function of PAK1 in modulating the actin cytoskeleton and cell motility (1), expression of cytoplasmic PAK1 in primary adenocarcinomas was associated with nodal metastasis (P = 0.03), and elevated PAK1 levels were more frequent in nodal metastases than primary tumors (P < 0.0001) (Table 1) . Also, as suggested by DNA copy-number analysis (Table S1 ), PAK1 protein levels were higher in nonbasal breast tumors than basal tumors and independent of cyclin D1 nuclear expression as determined by IHC (Tables S2-S6) . Lastly, RNA was purified from 88 primary breast cancer specimens, and cytoplasmic PAK1 IHC staining was correlated with increased mRNA expression (Fig.  S2F ). These data show that PAK1 expression is broadly upregulated in breast cancer and that high expression is correlated with disease progression.
Expression of PAK1 protein was also analyzed on tissue microarrays of 27 SCLC and 97 NSCLC, the latter being comprised of 30 adenocarcinomas and 67 squamous cell carcinomas; 43 of 67 (64%) squamous NSCLC samples were positive for PAK1 expression, and 52% of all cases showed staining of moderate (2+) or strong (3+) intensity in the malignant cells ( Fig. 2A , Table 1, and Tables S2-S6 ). Nuclear localization of PAK1 was also evident in a significant proportion of squamous NSCLCs (17/67; 25%). In contrast to squamous cell carcinoma, NSCLC adenocarcinomas (P = 0.0008) and SCLCs (P = 0.003) expressed only weak to moderate levels of PAK1 in the cytoplasm only. Adjacent normal lung tissue did not express appreciable levels of PAK1 ( Fig. 2 and Fig. S2E ). Interestingly, elevated PAK1 expression was also prevalent (79/130; 61%) in head and neck tumors, an additional indication of squamous cell carcinoma (Table 1 and Tables S2-S6 ). Additional evidence that PAK1 expression is elevated in squamous NSCLC was obtained by analyzing PAK1 mRNA expression in a distinct set of 54 lasercapture microdissected lung tissues, and PAK1 mRNA expression was highest in squamous NSCLC (P < 0.0001 compared with normal lung) (Fig. 2B) . Together, these results suggest that PAK1 overexpression in squamous carcinomas may occur through multiple molecular mechanisms such as increased transcription or protein translation and stability. (Fig. 2C) . Furthermore, we made use of a doxycycline-inducible shRNA system (21) to deplete endogenous target protein and further study PAK1 loss of function effects in squamous NSCLC. PAK1 and/or PAK2 shRNAs were introduced into NCI-H520.X1 (a subline of NCI-H520 that was selected for robust in vivo growth) and EBC-1 cells. As a negative control, cell lines containing LacZspecific shRNA were generated in parallel. Tightly regulated Doxmediated knockdown of target protein expression was observed for cell lines expressing shPAK1 and shPAK2 ( Fig. S3 A and B) . Inhibition of PAK1 but not PAK2 significantly reduced proliferation of NCI-H520.X1 and EBC-1 cells (*P < 0.0001) (Fig.  S3C) , supporting a role for PAK1 as a driver of proliferation in the squamous NSCLC subtype.
To better assess the mechanism by which PAK1 contributes to cellular proliferation, the cell-cycle profile of NCI-H520.X1 cells was determined by propidium iodide staining and fluorescenceactivated cell sorter analysis. After PAK1 inhibition, cells exhibited accumulation in G 1 phase (Fig. 2D ). In agreement with this result, levels of the E2F1 transcription factor, which is essential for G 1 /S progression and known to regulate gene expression associated with DNA replication and mitosis (22) , were also diminished as a consequence of PAK1 ablation (Fig. 2E ). Functional classification of global gene expression differences after PAK1 inhibition revealed the down-regulation of Molecular Signature Database (MSigDB) gene sets for E2F1 targets and serum-induced cell-cycle progression ( Fig. S3 D and E) . Furthermore, analysis of serum-starved quiescent NCI-H520.X1 cells also revealed an accumulation of the CDK1 inhibitor, p27 Kip1 , in the absence of PAK1 ( Fig. 2E; lane 6) . Even 24 h after cell-cycle reentry, the levels of p27 Kip1 remained elevated in protein lysates of cells lacking PAK1 ( Fig. 2E ; lane 10) compared with controls. Additional quantification of p27 Kip1 accumulation was performed by immunofluorescence staining and image analysis to detect nuclear p27 Kip1 in cells depleted for PAK1 (Fig. 2F ). An intense signal for nuclear p27
Kip1 was evident for NCI-H520.X1-shPAK1 cells treated with Dox in the presence or absence of serum (P < 0.05 and P < 0.0001, respectively) (Fig. 2F) . Taken together, the functional consequences of PAK1 blockade encompasses pronounced cytostatic effects in squamous NSCLC cells.
Antitumor Efficacy of PAK1 Inhibition in Preclinical Tumor Models of Squamous NSCLC. To extend our in vitro observations, the roles of PAK1 and PAK2 in tumor growth and maintenance were evaluated using NCI-H520.X1 and EBC-1 xenograft models ( Fig. 3 A  and B) . After tumor establishment, animals were administered Dox in sucrose drinking water, and tumor growth was monitored for 21-24 d. For NCI-H520.X1 tumor-bearing animals, inhibition of PAK1 but not PAK2 significantly impaired tumor growth relative to control shLacZ mice (P < 0.0001) (Fig. 3A) . Combined knockdown of PAK1 and PAK2 resulted in inhibition of tumor growth that was comparable with that of PAK1 inhibition alone (63.7% and 59.7%, respectively). Equivalent results were obtained using EBC-1 tumor xenografts, and 66.8% inhibition of tumor growth was observed after in vivo knockdown of PAK1 (Fig. 3B) . Furthermore, analysis of xenograft tumors by immunohistochemistry revealed a substantial decrease in K i -67-positive tumor cells in Dox-treated tumors expressing shPAK1 compared with shLacZ controls (Fig. 3C ). The proportion of K i -67-positive nuclei was quantified, and the antiproliferative effect of PAK1 knockdown in vivo was shown to be statistically significant (P < 0.01; NCI-H520.X1 shLacZ = 69 ± 6%, NCI-H520.X1 shPAK1 = 50 ± 4%, EBC-1 shLacZ = 91 ± 3%, EBC-1 shPAK1 = 75 ± 11%). PAK1 knockdown was not associated with decreased v-akt murine thymoma viral oncogene homolog (AKT) activation (Fig.  3D) , which has been suggested in recent literature (23) . PAK1-dependent changes in ERK/MAPK pathway activity or BAD protein phosphorylation were also not observed for squamous NSCLC cell lines, which is in contrast to PAK1 effector signaling in other cell types (Fig. S1 ) (12) . As such, we further investigated PAK1 signaling in squamous NSCLC cells using a reverse-phase protein array (RPPA) phosphoproteomics platform (Fig. S4A) . Decreased phosphorylation of NF-κB proteins was observed after PAK1 inhibition (Fig. S4 B and C) . The importance of PAK1 in NF-κB p105-Ser933 phosphorylation and nuclear accumulation of proteolytically processed NF-κB p50 was confirmed by cell fractionation and immunoblotting (Fig. S4D) . NF-κB can be induced by various signals, and the importance of this transcription factor in transformation of lung cancer cells has been recently reported (24) . Together, these findings show that PAK1 is critically important not only for proliferation of PAK1-overexpressing squamous NSCLC cells in vitro but also for tumor growth in vivo. The data also support the conclusion that interfering with PAK1 signaling could have therapeutic efficacy in squamous lung cancer.
Combination of PAK1 Inhibition with Molecularly Targeted Therapeutics Induces Apoptosis of NSCLC Cells. Given that single-agent PAK1 inhibition did not increase apoptosis of NSCLC cells and xenograft models, we hypothesized that PAK1 inhibition may synergize with other molecularly targeted agents to augment killing of tumor cells. We also reasoned that testing the combination of PAK1 inhibition plus compounds of known cellular mechanism would aid in understanding the cellular function of PAK1 in NSCLC cells as well as in rationally designing effective combination regimens that could be translated into the clinic. Hence, a cellular viability screen was performed using EBC-1-shPAK1 isogenic cells and a panel of 200 small-molecule compounds that included oncology drugs approved by the Food and Drug Administration (FDA), signaling pathway inhibitors, and DNA damaging agents (Table S7) . Among the tested compounds, antagonists of inhibitor of apoptosis proteins (IAP; 12-and 57-fold), epidermal growth factor receptor (EGFR; 2.9-, 7.4-, 12.8-, and 15-fold), MEK1/2 (8.5-fold), and Src family kinases (5.4-fold) displayed dramatically enhanced efficacy in the context of combined PAK1 knockdown ( Table 2 ). None of these agents showed a profound single-agent effect (EC 50 > 6 μM) on the growth and survival of EBC-1 cells in the absence of PAK1 knockdown. Thus, PAK1 inhibition can greatly augment the efficacy of several classes of well-characterized molecularly targeted therapeutics.
Antagonists of PAK1 and IAP Proteins Strongly Induce Apoptosis of NSCLC Cells. The prosurvival activity of IAP proteins is antagonized by the second mitochondrial activator of caspases (SMAC), and a number of antagonists have been described that mimic SMAC amino-terminal peptides to disrupt the association of IAP with SMAC and activated caspase-9 (25). In particular, BV6 represents one such class of small-molecule antagonists that binds to baculovirus IAP repeat (BIR) domains and promotes rapid autoubiquitination and proteasomal degradation of c-IAP1 and c-IAP2 (26) . Consistent with the small-molecule screening data, strong combinatorial activity was confirmed for dual inhibition of PAK1 and IAP in EBC-1 cells (Fig. 4A ). This dramatic increase in BV6 potency on EBC-1-shPAK1 cells when cotreated with Dox (EC 50 = 4.1 × 10 −7 μM) relative to controls (EC 50 = 3.0 × 10 −3 μM) translated into a strong induction of cellular apoptosis as determined by Annexin-V flow cytometry assay ( Fig. 4B and Fig.  S5A ) and immunoblotting for cleaved caspases-3, -6, -7, and -9 ( Fig. S5B) . Importantly, evidence of enhanced cell killing was also observed using pharmacological inhibitors of PAK (IPA-3) or Rac1 (NSC23766) catalytic activity ( Fig. 4C and Fig. S5 C and D, PF-3758309) (27) (28) (29) . To further explore this apparent synergy, we investigated possible molecular mechanisms of PAK1 and IAP inhibition on the induction of apoptosis. Combined PAK1 and IAP inhibition did not involve either altered kinetics of IAP protein degradation induced by BV6 (Fig. S5E) or autocrine signaling by TNFα, a known mediator of cell death induced by IAP antagonists (Fig. S5F ). Given that XIAP is not dependent on TNF receptormediated signaling for antiapoptotic activity and is a highly potent, endogenous inhibitor of caspases-3, -7, and -9 (30), we examined the contribution of this IAP family member to combinatorial efficacy through siRNA-mediated inhibition. Selective antagonism of XIAP together with PAK1 inhibition resulted in decreased cell viability ( Fig. 4D ) and prominent activation of effector caspases ( Fig. 4E ) that was comparable with combination with BV6 pan-IAP antagonist. Additional NSCLC cell lines, including those that are only minimally responsive to the activity of either single agent, Kip1 (red) and DAPI (blue) immunofluorescence after PAK1-inducible knockdown. Quantification of p27
Kip1 nuclear accumulation (n = 2,000 cells). *P < 0.05. **P < 0.0001. were further examined for antitumor efficacy resulting from combined inhibition of PAK1 and IAP. Transient siRNA-mediated knockdown of PAK1 expression followed by BV6 treatment resulted in a significant reduction of SK-Mes-1 and NCI-H441 cell viability (Fig. 4F ). Taken together, these studies provide strong preclinical support that NSCLC may provide several opportunities for rational combination therapies with PAK1 inhibitors.
Discussion PAK family kinases have been suggested to be central players in growth factor signaling networks, and this model raises the possibility that interfering with PAK1 activity could produce significant antitumor activity (31, 32) . We initiated the present study to help further clarify the contribution of PAK1 signaling to tumorigenesis. As a starting point, PAK1 genomic copy number and protein expression level were ascertained in 216 and 537 human tumor samples, respectively. In the context of breast cancer, PAK1 genomic amplification was prevalent in luminal tumors ( Fig. 1 and Table S1 ), and elevated cytoplasmic protein expression was observed across 39% of primary breast adenocarcinomas; it was associated with lymph node invasion and occurred more frequently in nodal metastases compared with primary tumors (P < 0.0001) (Tables S2-S6 ). It is interesting that the frequency of dysregulated expression of PAK1 was more frequent than would be predicted by genomic amplification alone, and additional regulatory mechanisms that may increase PAK1 expression in breast cancer, such as through microRNA genes (33), remain to be fully explored. Analysis of cell lines with PAK1 genomic copy-number gain revealed exquisite dependence on PAK1 expression and activity for cell survival ( Fig. 1 C and  D) . The prosurvival function of PAK1 in breast cancers might be another contributing factor to the association of elevated PAK1 expression and reduced clinical benefit in patients treated with tamoxifen (34) . Although genomic amplification of the 11q13 region has previously been reported in breast cancer (35) , the high sensitivity of our SNP array analysis, correlation with IHC data, and loss of function mechanistic studies showing apoptosis after single-agent PAK1 inhibition ( Fig. 1 and Table S1 ) significantly refine our understanding of PAK1 genomic lesions in this tumor indication. Taken together, our identification of PAK1 as an Achilles' heel for a subpopulation of breast cancer provides evidence of oncogene addiction (20) and a rationale for PAK1-directed therapy in this disease indication.
Herein, we also show that lung and head and neck squamous carcinomas have aberrant cytoplasmic expression of PAK1 (52% and 61%, respectively) ( Fig. 2 and Table 1 ). It is interesting that nuclear translocation of PAK1 was also observed across squamous tumor subtypes, including NSCLC (25%; n = 67) and HNSCC (42%; n = 130) (Tables S2-S6 ). The biological function of PAK1 in the nucleus is presently not well-understood; however, it has been shown that nuclear import of PAK1 can play a critical role in vertebrate development (36) . Loss of function studies to analyze the role of PAK1 in squamous NSCLC cells revealed a requirement for PAK1 in cytoskeletal reorganization, including paxillin phosphorylation, focal adhesion turnover, and cell motility (Fig. S6 ) as well as cell-cycle progression (Fig. 2 C  and D) . E2F and p27
Kip1 are known to play multifaceted roles in regulation of G 0 -to S-phase transitions of the cell cycle (22, 37), and the cellular levels of these proteins were significantly affected by PAK1 inhibition in squamous NSCLC cells (Fig. 2E) . Altered expression of a large number of putative E2F-responsive genes, including gene clusters with well-established functions in cell-cycle regulation, DNA replication and repair, mitosis, and mitotic spindle checkpoint controls (38) , further support PAK1-mediated regulation of E2F transcription factors as a proliferative mechanism for squamous NSCLC cells (Fig. S3) . Inhibition of PAK1 signaling also resulted in accumulation of p27 Kip1 in the nucleus (Fig. 2F) . Nuclear localization of p27 Kip1 is required for its tumor suppressor activity, and several oncogenic pathways are known to diminish nuclear levels of p27
Kip1 to drive tumor growth and cell-cycle progression (37) . Consistent with these cell-culture experiments, inducible knockdown of PAK1 in vivo also resulted in stasis of established NCI-H520.X1 and EBC-1 xenograft tumors (Fig. 3) .
At present, known genetic aberrations in squamous NSCLC include p53, p16
Ink4a , phosphatase and tensin homolog (PTEN), and serine-threonine kinase 11 (STK11) loss of function through mutation or methylation and activating mutations, amplification, or overexpression of protein kinases such as EGFR, MET, HER2, and PIK3CA (39) . This raises the question of whether inhibition of PAK1 enzymatic activity or scaffold function might combine synergistically with therapeutic agents that target these critical growth and survival pathways to increase antitumor efficacy and tumor cell death. Small-molecule library screening was used to address this question, and PAK1 ablation rendered NSCLC cells hypersensitive to antagonists of IAP, EGFR, and Src signaling ( Table 2 ). The mechanism of action for combinatorial efficacy of PAK1 and IAP antagonism was further investigated and involves inhibition of PAK1 enzymatic activity and synergistic induction of apoptosis ( Fig. 4B and Fig. S5 A-D) . The apoptotic phenotype resulting from PAK1 and IAP combined inhibition differs substantially from the antiproliferative effect that is observed after single-agent inhibition of PAK1 in squamous NSCLC cell lines (model depicted in Fig. S5G ). Because small-molecule antagonists of both PAK and IAP proteins have entered clinical trials (28, 40) , the potential synergy of this combination therapy can be investigated in patients. Interestingly, PAK1 signaling in squamous NSCLC cells was also associated with an accumulation of the antiapoptotic BCL2 family member, myeloid cell leukemia-1 (Mcl-1) (Fig. 2E) , and suggests another mechanism for PAK1 inhibition in regulation of cell survival and therapeutic combinations with BCL2 inhibitors currently in clinical evaluation, such as Navitoclax/ABT-263 (41) .
In addition to suggesting beneficial combination therapies for preclinical follow-up, the chemical-genetic approaches that we used allow for insights into the molecular mechanism of PAK1 inhibition in tumor cells. Given that the squamous histologic subtype comprises at least 30% of new NSCLC cases in the United States, our findings have important implications for the development of strategies and agents for the treatment of lung cancer. Taken together, the results from our tumor analysis and preclinical models provide evidence for potential antitumor efficacy of PAK1 inhibition. Immunohistochemistry Analysis of Patient Tumor Samples. Immunohistochemistry (IHC) was performed as described previously (2) . In brief, antigen retrieval was performed by incubating slides in Tris·EDTA, pH 9.0, under 15 psi pressure for 2 min using a Decloaking Chamber (Biocare Medical). Sections were incubated for 16 h at 4°C with a primary anti-P21-activated kinase 1 (PAK1) rabbit polyclonal antibody at 1:100 dilution (catalog number 2602; Cell Signaling Technology). Bound antibody was labeled with anti-rabbit/mouse Envision (DAKO). IHC was also performed for cyclin D1 on the breast cancer series using the Ventana Discovery (Ventana Medical Systems). In brief, antigen retrieval was performed with CC1 mild antigen retrieval solution. Sections were incubated with an anticyclin D1 rabbit antibody at 0.331 μg/mL (clone SP4; DAKO). Bound antibody was labeled with Omnimap anti-rabbit horseradish peroxidase (Ventana Medical Systems). Antibody complexes were visualized using 2,3-diaminobenzidine chromogen, and sections were counterstained with Mayer's hematoxylin. Intensity of PAK1 expression was scored separately in the cytoplasm and nuclei of neoplastic cells on a scale of 0-3. The highest intensity score among replicate cores was used as the score for each patient. The same pathologist (A.J.) scored all cases and was blind to the clinical data. The χ 2 test was used to evaluate associations between categorical variables.
Materials and Methods
Genome Copy-Number and Microarray Expression Analysis. For the Affymetrix 500K SNP array analysis, genomic DNA preparation, chip processing, and data analysis were performed as published previously (3) . Regions of significant gains or losses were identified using the Genomic Identification of Significant Targets in Cancer (GISTIC) algorithm (4). The GISTIC Q values for DNA gain are defined by the multiple testing-corrected probability of gain frequency and mean copy gain occurring by chance displayed as the negative log 10 of the Q value for each SNP array probe set. To collect expression array data for matched tumor samples, RNA was extracted from frozen tissue from 88 cases of the primary breast cancer series and applied to Affymetrix HGU133 gene expression microarrays. Gene probe intensity data were used to subclassify the tumors into basal, luminal-A, luminal-B, Her2, and normal types according to published criteria (5).
Complementary RNA was also synthesized from 9 normal, 29 adenocarcinoma NSCLC, and 16 squamous NSCLC samples and hybridized to Affymetrix U133 Plus 2.0 microarray chips. The 226507_at probe set was chosen to represent PAK1 mRNA expression. Data for 226507_at probe intensity are plotted as the mean (horizontal line), middle 50% of data (box), and 95% confidence interval (lines). Pair-wise comparisons were performed by Student t test. To ascertain the role of PAK1 in cell survival, the quantity of cytoplasmic histone-associated DNA fragments was quantified using the Cell Death Detection ELISA Plus kit from Roche. Alternatively, for cell death analyses by flow cytometry, cells were collected by centrifugation and stained with Annexin V-FITC and PI solution (BD Biosciences) according to the manufacturer's instructions. Annexin V labeling (bottom-right quadrants) represents the population undergoing early apoptosis. Annexin V and PI double labeling (top-right quadrants) represents cells that have already died by apoptosis. Live cells are represented in the bottom-left quadrants.
For the pharmarray viability screen using a 200-compound library, EBC1-shPAK1 cells were cultured in complete growth medium and either untreated or treated with 300 ng/mL doxycycline for 3 d before compound addition. Cells were then replated at appropriate density in 384-well plates and treated with six concentrations (fourfold serial dilutions from 10 μM) of each compound for 72 h of treatment. Cell viability was assessed by ATP content using the CellTiter-Glo Luminescent Assay (Promega). Cell growth inhibition and EC 50 differences were determined for PAK1 knockdown and WT cells. Cells were also transfected with nontargeting control (NTC) or X chromosome-linked inhibitor of apoptosis (XIAP) -specific siRNA oligonucleotides for 48 h before treatment with DMSO or PAK small-molecule inhibitor (SMI) as indicated for an additional 72 h. Cell viability was determined by Cell Titer Glo assay, and results represent mean ± SD from three experiments. . Inducible shRNA-bearing lentivirus constructs were made based on previously described methods (6, 7) by cotransfecting H1 or U6 short hairpin plasmid (pHUSH)-Lenti-GFP and/or pHUSH-Lenti-dsRed constructs containing a desired shRNA with plasmids expressing the vesicular stomatitis virus (VSV-G) envelope glycoprotein and HIV-1 packaging proteins (GAG-POL) in HEK293T cells using Lipofectamine (Invitrogen). Target cells were transduced with these viruses and sterile-sorted (top 2-5%) by flow cytometry for presence of dsRed, GFP, or both. Cells were characterized for doxycycline-inducible protein knockdown by Western blot analysis.
Immunoblotting and Immunofluorescence. Frozen tumors were pulverized on dry ice using a small Bessman tissue pulverizer (Spectrum Laboratories), and protein extracts were prepared at 4°C with Cell Extraction Buffer (Invitrogen), 1 mM PMSF, Phosphatase Inhibitor Mixture 1/2 (Sigma-Aldrich), and one tablet Complete EDTA-Free Mini protease inhibitor mixture (Roche Diagnostics). Lysates were subjected to centrifugation at 16,100 × g for 15 min, and protein concentration was determined using the bicinchoninic acid (BCA) protein assay (Pierce Biotechnology). For Western blot analysis, proteins were resolved by 4-12% SDS/PAGE and transferred to nitrocellulose membranes (Millipore). Immunoblotting was performed using primary antibodies for PAK1, p27, E2F1, Mcl-1 (Cell Signaling Technology), and anti-β-actin (Sigma-Aldrich). Secondary antibodies were obtained from Pierce Biotechnology.
Immunofluorescence imaging was performed using primary antibodies for p27 Kip1 (Becton Dickinson). Secondary antibodies were obtained from Millipore. Images were analyzed in Metamorph (version 7.5.3.0; MDS Analytical) using an automated analysis routine. Briefly, a smoothing filter was applied to the DAPI channel to even out the nuclear staining pattern. The MWCS application in Metamorph was then used to identify and count DAPI-stained nuclei and classify them as positive or negative for p27 in the Cy3 channel.
Tumor Xenograft Models. Cultured NCI-H520.X1 and EBC1 cells were removed from culture, suspended in HBSS, mixed 1:1 with Matrigel (BD Biosciences), and implanted s.c. into the right flank of naïve female nude mice (Taconic Farms). Mice with tumors of a mean volume of ∼250 mm 3 were grouped into treatment cohorts of 10 mice each. Mice received 5% sucrose only or 5% sucrose plus 1 mg/mL doxycycline (Clontech) for control and knockdown cohorts, respectively. All water bottles were changed three times per week. Body weights and tumor volume measurements (as obtained by length and width measurements with calipers) were taken two times per week during the study. No animal weight loss was observed. All experimental procedures conformed to the guiding principles of the American Physiology Society and were approved by Genentech's Institutional Animal Care and Use Committee. . Data analysis and generation of P values using the Dunnett t test were done using JMP software (SAS Institute). Tumor progression data for both xenograft models were also analyzed for the time required for tumor size to double from the onset of treatment. By this metric, PAK1 inhibition also resulted in a statistically significant antitumor effect compared with the other cohorts. Individual mice were removed from data plotting when tumors reached a volume end point of 2,000 mm 3 : NCI-H520.X1 shLacZ control (n = 5), shLacZ+ Dox (n = 3), shPAK1 control (n = 2), shPAK2 control (n = 5), shPAK2+Dox (n = 2), and shPAK1+2 control (n = 5).
For histologic analysis of in vivo knockdown of PAK1 in NCI-H520.X1 and EBC-1 tumors, tumor-bearing mice were administered Dox, and on day 7, the tumor tissue was harvested. Xenograft tissues were fixed for 24 h in 10% neutral buffered formalin and were then processed and paraffin-embedded. Sections were cut at a thickness of 3 μm, and specimens with sufficient viable tumor (assessed on H&E-stained slides) were further evaluated by IHC. Anti-K i -67 (clone MIB-1, mouse anti-human) was used with the DAKO ARK Kit for detection. Tissues were counterstained with hematoxylin, dehydrated, and mounted. Antigen retrieval was done with the DAKO Target Retrieval Kit as per the manufacturer's instructions. For quantification of immunohistochemically K i -67-positive cells, images were acquired by the Ariol SL-50 automated slide-scanning platform (Genetix) at 100× final magnification. Tumor-specific areas were identified manually for analysis in the Ariol software. A 3,3′-diaminobenzidine-specific color range was specified using the hue, saturation, and intensity color space to quantify the area of staining, and the output was total K i -67-positive cells in relation to total cell count.
Reverse-Phase Protein Arrays. Protein lysates were analyzed by reverse-phase protein array (RPPA) by Theranostics Health, LLC. All samples were diluted to a final concentration of 0.5 mg/mL, and sample dilutions were printed in duplicate on slides. The slides were then subjected to immunostaining with a panel of 100 antibodies primarily directed against specific phosphorylated or cleaved proteins. Each of these antibodies had previously undergone extensive validation for both phosphorylation and protein specificity using single-band detection at the appropriate molecular weight by immunoblotting. The intensity value for each end point was determined by identifying spots for each duplicate dilution curve for each sample that was within the linear dynamic range of the staining after backgroundsubtractionwitheachspot(withinslidelocalbackground and also against a slide stained with secondary antibody only). Each value was normalized relative to the total protein intensity value for that sample derived from a slide stained with Sypro Ruby (Invitrogen). RPPA data were processed by log2 transformation and linear scaling (z score conversion) to ensure normality and linearity. S2 . Validation of the PAK1 immunohistochemistry assay. Specificity of PAK1 detection was confirmed by comparison of immunoblot and immunohistochemical staining data. NCI-H520, HCC-1500, HCC-1419, and MCF-7 cells were analyzed by (A) Western blotting and (B) immunohistochemistry for PAK1 expression using an antibody against human PAK1. Consistent with immunoblot results, formalin-fixed paraffin-embedded NCI-H520, MCF-7, and HCC-1500 cells exhibited cytoplasmic staining, with the strongest PAK1 staining seen in NCI-H520 and HCC-1500 cells. HCC-1419 cells were negative for PAK1 staining. No notable specific or nonspecific staining was exhibited in the cell pellet isotype controls. NCI-H520.X1-shPAK1 cells cultured in the presence or absence of doxycycline to induce PAK1 knockdown were used as additional controls for (C) immunoblotting and (D) IHC staining with anti-PAK1 antibody. (E) Overview of PAK1 immunohistochemical analysis of human tumors. PAK1 staining intensity varied among tumor tissues, ranging from no or low staining to very strong staining in either the cytoplasm and/or nucleus. Representative images of immunohistochemistry for PAK1 in head and neck squamous cell carcinoma (a, negative; b, weak cytoplasmic and nuclear; c, moderate cytoplasmic; d, strong cytoplasmic and nuclear), breast adenocarcinoma (e, negative; f, weak cytoplasmic; g, moderate cytoplasmic; h, strong cytoplasmic), normal breast (i, negative), small cell lung carcinoma (j, negative; k, weak cytoplasmic; l, moderate Legend continued on following page Ong et al. www.pnas.org/cgi/content/short/1103350108
precipitation against a blue hematoxylin counterstain. (F) Immunohistochemical cytoplasmic PAK1 scores 2 and 3 show significantly higher PAK1 mRNA expression than scores 0 or 1. The box whisker plot compares PAK1 protein expression (cytoplasmic score of immunohistochemistry on formalinfixed paraffin-embedded tissue) with PAK1 mRNA expression (Affymetrix microarray data from frozen tissue) for 88 breast tumors. The difference in the mean of PAK1 immunohistochemistry cytoplasmic score 0 or 1 vs. score 2 or 3 was statistically significant (P = 0.004; Student t test). Median bar is shown with surrounding box (1 SD), whisker plots (2 SDs), and near (circle) and far (star) outliers. (24 h), cells were fractionated into cytosolic and nuclear lysates and blotted for levels of NF-κB p105 and p50 proteins. Nuclear levels of NF-κB p50 protein were significantly greater in the presence than the absence of PAK1. NF-κB essential modulator (NEMO) (cytosolic) and Lamin A/C (nuclear) expression were used as controls for subcellular fractionation and protein loading. (E) Squamous NSCLC cells are also sensitive to RNAi-mediated knockdown of NF-κB p105. EBC-1 viability was measured by Cell Titer Glo assay after transfection with either a nontargeting control siRNA oligonucleotide (NTC) or a pool of siRNA oligonucleotides against NF-κB1. Data are shown as the mean ± SD. Paxillin is a multidomain protein that localizes to focal adhesion sites, and phosphorylated Tyr118 provides a docking site for recruitment of other signaling molecules to focal adhesions. PAK1 is also involved in focal adhesion kinase (FAK) phosphorylation and is a possible mechanism for PAK1 regulation of EBC-1 cell motility. (C) PAK1 is required for EBC-1 cell motility. Cell migration was measured in Boyden chambers in serum-free media after 20 h. The experiment was performed in triplicate, and data are plotted as the mean (horizontal line), middle 50% of data (box), and 95% confidence interval (lines). Migration of Dox-treated shPAK1 cells was significantly reduced relative to controls (P < 0.05). Pair-wise comparisons were performed by Student t test. (D) PAK1 is required for HGF-induced actin dynamics in EBC-1 squamous NSCLC cells. EBC-1 cells were pretreated with Dox for 3 d before serum starvation for 16 h and treatment with 50 ng/mL hepatocyte growth factor (HGF) for 1 h. Inducible knockdown of PAK1 attenuated cell rounding, as quantified by measuring cell diameter by image analysis (P = 0.002). Induction of control LacZ shRNA with Dox had no effect in these assays. For each condition, at least 100 cells were quantified for cell-spreading phenotype. 
